EHMT2 and cancer: Based on the previous experience with epigenetic modulators in experimental cancer, it is possible that, in various circumstances, combination therapies using one G9a inhibitor plus cytotoxic chemotherapy, other epigenetic agents, or other classes of targeted agents will be revealed as more effective than single-agent therapies focusing on G9a inhibition alone.